Disc Medicine

DISC MEDICINE INC

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Disc Medicine Inc

Iron Mountain Incorporated (Delaware)Common Stock REIT

Iron Mountain Inc

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals Inc

IRON HORSE ACQ R

IRONBARK ZINC LTD ORD by Ironbark Zinc Ltd.

Iron Horse Acquisition Corp II Units (1 Ord Shs & 1 Rts)

Iron Horse Acquisition Corp II

Iron Horse Acquisitions Corp

Iron Horse Acquisitions Corp Units (1 Ord, 1 War & 1 Rts)

Iron Horse Acquisitions Corp Warrants (27/12/2028)

Iron Road Ltd

IronNet Inc

IronNet Inc Warrants (26/08/2026)

IRONSTONE GROUP INC by Ironstone Group, Inc.

Ironstone Properties Inc

Ironveld PLC

Health Care

Press Releases

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

Earnings

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

News

Financing

Management

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

General

Disc Medicine Announces Receipt of FDA Commissioner's National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IPOs

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

IRON

STTK

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ADMA Biologics

Alvotech

Apogee Therapeutics

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Beam Therapeutics

Celcuity

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Amicus Therapeutics

GRAIL

Immunovant

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Comments

Disc Medicine

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL